Anthrax drug under the microscope: new study tracks Real-World use
NCT ID NCT07478471
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will follow up to 10 people in the U.S. who have a confirmed case of systemic anthrax and are treated with the drug raxibacumab. Researchers will track survival, side effects, and drug levels in the blood to better understand how well the treatment works. Because anthrax is rare and unpredictable, most information will be gathered from medical records after treatment has already occurred.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- raxibacumab
- What this could lead to
- If successful, this study could provide real-world evidence on how well raxibacumab works against anthrax and help guide future treatment decisions.
- What could go wrong
- This is a very small observational study (only 10 patients) with no control group, so results may not be conclusive. Most data will be collected after the fact, which can limit reliability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS, BACTERIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.